{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl aminolevulinate
to a specific field?
Status:
Investigational
Source:
NCT00003853: Phase 2 Interventional Completed Multiple Myeloma and Plasma Cell Neoplasm
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iododoxorubicin is an anthracycline derivative patented by Farmitalia Carlo Erba S.p.A. for cancer treatment. In preclinical studies, Iododoxorubicin has demonstrated significantly reduced levels of cardiotoxicity compared to anthracyclines. Unfortunately, during phase II clinical trials Iododoxorubicin failed to demonstrate efficacy in an advanced breast cancer patient
Class (Stereo):
CHEMICAL (ACHIRAL)
Nanterinone [UK 61260], a phosphodiesterase III inhibitor, was undergoing II evaluation with Pfizer in the US for the treatment of heart failure. Nanterinone is a positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. Preliminary data from controlled studies suggest satisfactory long-term efficacy and safety.
Class (Stereo):
CHEMICAL (ACHIRAL)
Batelapine (or CGS 13429), an antipsychotic drug, that was undergoing preclinical development, but the further studied were discontinued
Status:
Investigational
Source:
NCT00043797: Phase 2 Interventional Unknown status Diabetic Polyneuropathy
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Lidorestat is a highly potent and selective aldose reductase inhibitor with good oral bioavailability that is reported to improve nerve conduction and reduce cataract formation. Lidorestat reduced mortality rates in hAR transgenic mice. Mice receiving lidorestat had similar survival rates as nonhAR-expressing diabetic mice. Lidorestat treatment did not affect plasma lipids, glucose, or weights of diabetic mice. Drugs such as lidorestat will improve human health by reducing the production of toxic products of the polyol pathway. Lidorestat was developed for the treatment of diabetic complications, including neuropathy, retinopathy, cataracts, nephropathy.
Status:
Investigational
Source:
NCT00838799: Phase 2 Interventional Completed Diabetic Peripheral Neuropathic Pain
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
RGH-896 (radiprodi) is orally active and selective NMDA NR2B antagonist, a potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions. It blocks pain signaling without interacting with other NMDA receptor subtypes thus potentially improving therapeutic index and side effect profile. RGH-896 is the first of this group and is currently in early clinical development. Forest and Richter initiated a Phase IIb study in neuropathic pain in the United Stated in the second half of 2006. The drug did not produce significant reductions in patient-reported pain scores for all the dosages tested. Forest says that it and Gedeon Richter will review the findings before making a decision about the further development of radiprodil. In addition to neuropathic pain, the companies intend to investigate various other pain conditions and possibly CNS indications not related to pain. Forest will pay Richter undisclosed upfront and milestone payments in addition to royalties and will have exclusive rights in the U.S. and Canada. The two companies will jointly fund the development program. RGH-896 has patent applications that provide patent protection until at least 2022.
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Spirotriazine is a dihydrotriazine derivative patented by Burroughs Wellcome & Co. (U.S.A.) Inc. as the anthelmintic agent. In preclinical models, Spirotriazine shows potent activity against intestinal parasites and negligible microbiological activity.
Status:
Investigational
Source:
NCT02452008: Phase 2 Interventional Active, not recruiting Prostate Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Galunisertib is a potent inhibitor of TGF beta type 1 receptor. The drug is under clinical development for the treatment of different cancers: pancreatic, hepatocellular, breast, rectal, prostate etc. and reached phase 2/3 in patients with myelodysplastic syndromes.
Status:
Investigational
Source:
NCT00112554: Phase 3 Interventional Completed Leukemia
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LAROMUSTINE is a sulfonylhydrazine alkylating agent. It is metabolized to yield a chloroethylating compound (VNP-4090-CE) and a carbamoylating compound (methyl isocyanate). The former is primarily responsible for the antineoplastic effect of LAROMUSTINE. It alkylates the O6 position of guanine, resulting in DNA crosslinking, strand breaks, chromosomal aberrations, and disruption of DNA synthesis. The carbamoylating species contribute to antitumor activity by inhibiting O6-alkylguanine transferase, an enzyme involved with DNA repair. It was studied in the treatment of several types of cancer, however, its development was discontinued.
Status:
Investigational
Source:
NCT00078013: Phase 2 Interventional Completed Myocardial Infarction
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction
Status:
Investigational
Source:
NCT00004057: Phase 1 Interventional Completed Lymphoma
(1998)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
L-778123 is a dual inhibitor of Farnesyl Protein Transferase (FPTase) and Geranylgeranyl Protein Transferase type-I (GGPTase-I), which can completely inhibit Ki-Ras prenylation. L-778123 has been used in phase I clinical trials to determine its effectiveness in treating patients with recurrent or refractory solid tumors. L-778123 was also studied in combination with paclitaxel to determine efficacy as a treatment for both recurrent or refractory solid tumors, and lymphomas.
